Thermo Fisher Scientific Inc has entered into a definitive agreement to acquire Solventum’s Purification & Filtration business for approximately US$4.1 billion in cash.
The Purification & Filtration business provides filters and membranes for use in the manufacturing of biopharmaceutical and medical technologies, microelectronics and food, beverage products and drinking water. It operates globally with sites across the Americas, Europe, the Middle East, Africa, and the Asia-Pacific region, and has approximately 2,500 employees. In 2024, Solventum’s Purification & Filtration business generated revenue of approximately US$1 billion.
Marc Casper, chairman, president and CEO of Thermo Fisher, said: “As the trusted partner to our customers, Solventum’s Purification & Filtration business will expand and add differentiated capabilities to our bioprocessing portfolio to better serve our customers in this rapidly growing market. We look forward to welcoming our new colleagues to Thermo Fisher.”
The transaction is expected to be completed by the end of 2025, subject to regulatory approval and customary closing conditions.
Once the deal closes, the Purification & Filtration business will become part of Thermo Fisher’s Life Sciences Solutions segment.
